Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib

Abstract

The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the efficacy and safety of sorafenib as a systemic treatment in these patients is still under debate. We performed a concise review of sorafenib therapy in this population. However, it is important to make any decisions on treatment for elderly patients with HCC through a multidisciplinary team that includes experts in the liver disease. Patients with good clinical conditions should be treated with sorafenib.

Keywords

Hepatocellular carcinoma / sorafenib / treatment / chemotherapy / elderly patients

References

[1] International Agency for Research on Cancer. GLOBOCAN 2012 Cancer Fact Sheets. Available from: http://www.globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx. [Last cited on 2015 Apr 27].

[2] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[3] Michielsen PP,van Dongen JL.Viral hepatitis and hepatocellular carcinoma..World J Surg Oncol2005;3:27 PMCID:PMC1166580

[4] Bosch FX,Díaz M.Primary liver cancer: worldwide incidence and trends..Gastroenterology2004;127:S5-16

[5] Degos F,Ganne-Carrie N,Degott C,Trinchet JC,Chevret S.Hepatitis C virus related cirrhosis: time to occurrence to hepatocellular carcinoma and death..Gut2000;47:131-6 PMCID:PMC1727946

[6] El-Serag HB,Petersen NJ.The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update..Ann Intern Med2003;139:817-23

[7] Yancik R,Varricchio CG.Perspectives on comorbidity and cancer in the older patient: approach to expend the knowledge base..J Clin Oncol2001;19:1147-51

[8] Dale W,Eldadah BA,Schilsky RL,Muss HB,Ferrell B,Nayfield SG.Biological, clinical, and psychosocial correlates at the interface of cancer and aging research..J Natl Cancer Inst2012;104:581-9 PMCID:PMC3328422

[9] Townsley CA,Oza AM,Winquist E,Degendorfer P,Siu LL.Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination..Clin Cancer Res2006;12:2141-9

[10] European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[11] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Häussinger D,Shan M,Voliotis D.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[12] Cheng AL,Chen Z,Qin S,Luo R,Ye S,Xu J,Liang H,Wang J,Pan H,Zou J,Guan Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo controlled trial..Lancet Oncol2009;10:25-34

[13] Lencioni R,Ye SL,Chen XP,Furuse J,de Guevara LL,Takayama T,Nakajima K,Heldner S.GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis..Int J Clin Pract2014;68:609-17 PMCID:PMC4265239

[14] Di Costanzo GG,De Luca M,Lampasi F,Picciotto FP,Mattera S,Ascione A.Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma..Med Oncol2013;30:446

[15] Edeline J,Le Sourd S,Brunot A,Cattenoz C,Gédouin D,Boucher E.Sorafenib use in elderly patients with hepatocellular carcinoma: Caution about use of platelet aggregation inhibitors..Cancer Chemother Pharmacol2015;75:215-9

[16] Jo M,Kirishima T,Niimi T,Mori T,Sumida Y,Takami S,Mitsumoto Y,Yamaguchi K,Mizuno M,Tanaka S,Kagawa K,Itoh Y.Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma..Hepatol Res2014;44:1329-38

[17] Montella L,Cennamo G,Palmieri R,Sperlongano R,Russo P.Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series..Oncology2013;84:265-72

[18] Francini E.Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC)..Hepatology2014;60:764-5

[19] Morimoto M,Kondo M,Takada J,Kobayashi S,Okuse C,Taguri M.Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib..Hepatol Res2011;41:296-302

[20] Wong H,Yao TJ,Leung R,Cheung TT,Pang RW,Fan ST.The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC)..Oncologist2011;16:1721-8 PMCID:PMC3248771

[21] Germano D,Barletta E,Daniele B.Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib..Drugs Aging2013;30:887-92

[22] Cabibbo G,Cammà C.Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?.Expert Rev Anticancer Ther2013;13:1355-61